Summary: The diagnosis of early (non-metastatic) 
Introduction
The choice of immediate or deferred therapy for patients with early (non-metastatic) prostatic cancer is dependent upon two factors -diagnosis of the condition at an early stage and a conviction that effective therapy is available.
In the United Kingdom there is no generally available screening programme for the detection of asymptomatic prostatic cancer at a time when it might be amenable to all treatment options including radical surgical excision. The earlier stages of disease will inevitably be found more commonly in the younger patients. If it can be established that early therapy influences the survival early diagnosis will be mandatory.
Once the diagnosis has been made treatment can be given. That which is chosen will be determined in part by the professional training and inclination of the doctor in charge ofthe patient and in part by a general perception of the effectiveness of the alternative therapeutic regimens. The major options are shown in Table I and include deferred treatment, radical surgery, radiotherapy and hormonal therapy. At the present time chemotherapy is not a viable option as it is not yet sufficiently effective.
From Table I it can be seen that none of the options is ideal. The choice of compromise will be determined by the hazard which is acceptable to the patient and the benefit that he may expect from the therapy.
Only when the choice of treatment has been decided does the question of its timing become of great relevance. This paper analyses the evidence in favour of the different forms of treatment and considers the possible place of deferred therapy.
The basis of effective cancer control is to excise the primary tumour whilst it is still confined or to destroy it in situ by irradiation. This ideal has led to the use of radical prostatectomy and radical radiotherapy in lesions confined to the prostate. If Although the total number of patients in these studies was small and even though the numbers in each group were not identical despite randomization the authors felt able to conclude that: (a) radiotherapy at diagnosis was less effective than radical operation in delaying progression in those with node-negative disease limited to the prostatic capsule; (b) delayed hormonal therapy was as effective as external radiotherapy in node-positive patients whose primary tumour was limited to the prostatic capsule, and that (c) hormonal therapy and radiotherapy appeared to be equally effective in delaying progression in patients with node-negative disease whose primary lesion was beyond the prostatic capsule.
The fact that the progression rate was more rapid in those receiving radiotherapy than in those treated by In taking a decision to treat, one must inevitably accept that the patient's quality of life will be affected by the treatment and understand that radical surgery and radical radiotherapy may both be followed by long-term complications which include incontinence, impotence, bladder contracture, urethral stricture and irradiation proctitis. It is-by no means certain that radiotherapy is effective in controlling disease localized to the prostate especially if it is poorly differentiated and it is unlikely that radical prostatectomy has much to offer the patient if over the age of 70 at the time of diagnosis since the advantages in terms of survival are seen only after ten years.8 Many elderly patients are doubtless best left untreated. The management of the younger patient must, however, be different since death is most likely to occur from disseminated prostatic cancer. In such patients radical excision of the prostate is an attractive option.
For those whose disease is beyond the capsule at the time of diagnosis logical evidence in favour of, or against, treatment at first presentation should become available from the results of the MRC trial within the next five years. The outcome of this study may be one of the most important contributions to the management of prostatic cancer within the last forty years.
